Use of metabolic drugs and fish oil in HIV-positive patients with metabolic complications and associations with dyslipidaemia and treatment targets

HIV Medicine

Volumn 8, Issue 6, 2007, Pages 346-356

  Normén, Lena ^a   Yip, B ^a   Montaner, J ^a,b   Harris, M ^a   Frohlich, J ^a,b   Bondy, G ^a,b   Hogg, R S ^a,b  

^a ST PAUL S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Dyslipidaemia; Fibrates; Fishoil; HIV; Statins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; FIBRIC ACID DERIVATIVE; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN SENSITIZING AGENT; LIPID; METFORMIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DRUG USE; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; FISH OILS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 34547467108     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00449.x     Document Type: Article

References (57)

1. UNAIDS. 2004 Report on the Global AIDS Epidemic. http://www.unaids.org/ bangkok2004/GAR2004_html/ExecSummary_en/ExecSumm_en.pdf 2004.
2. Hogg RS, Yip B, Kully C et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. Can Med Assoc J 1999; 160: 659-665.
3. Flynn TE, Bricker LA. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 1999; 131: 548.
4. Behrens G, Schmidt HH, Stoll M, Schmidt RE. ApoE genotype and protease-inhibitor-associated hyperlipidaemia. Lancet 1999; 354: 76.
5. Eriksson U, Opravil M, Amann FW, Schaffner A. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients? AIDS 1998; 12: 2079-2080.
6. Henry K, Melroe H, Huebsch J et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328.
7. Barbaro G, Di Lorenzo G, Cirelli A et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther 2003; 25: 2405-2418.
8. Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-512.
9. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
10. Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr 2002; 30: 440-447.
11. Fontas E, van Leth F, Sabin CA et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189: 1056-1074.
12. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-262.
13. Meng Q, Lima JA, Lai H et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002; 144: 642-648.
14. Seminari E, Pan A, Voltini G et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002; 162: 433-438.
15. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356: 1423-1430.
16. Saves M, Chene G, Ducimetiere P et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-298.
17. Hsue PY, Giri K, Erickson S et al. Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004; 109: 316-319.
18. Moyle GJ, Buss NE, Gazzard BG. Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy. J Acquir Immune Defic Syndr 2002; 30: 460-462.
19. Stein JH, Merwood MA, Bellehumeur JL et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 2004; 147: E18.
20. Baldini F, Di Giambenedetto S, Cingolani A, Murri R, Ammassari A, De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: A pilot study. AIDS 2000; 14: 1660-1662.
21. Benesic A, Zilly M, Kluge F et al. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: Comparison of efficacy and interaction with indinavir. Infection 2004; 32: 229-233.
22. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers. ACTG Study A5047. AIDS 2002; 16: 569-577.
23. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352: 1031-1032.
24. Melroe NH, Kopaczewski J, Henry K, Huebsch J. Intervention for hyperlipidemia associated with protease inhibitors. J Assoc Nurses AIDS Care 1999; 10: 55-69.
25. Calza L, Manfredi R, Chiodo F. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART. Infection 2002; 30: 26-31.
26. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: Frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect 2001; 42: 181-188.
27. Bonnet F, Balestre E, Thiebaut R et al. Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med 2004; 5: 133-139.
28. Hellerstein MK, Wu K, McGrath M et al. Effects of dietary n-3 fatty acid supplementation in men with weight loss associated with the acquired immune deficiency syndrome: Relation to indices of cytokine production. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 258-270.
29. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 13: 1000-1002.
30. Hadigan C, Meigs JB, Rabe J et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86: 939-943.
31. Walli R, Michl GM, Muhlbayer D, Brinkmann L, Goebel FD. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 2000; 199: 253-262.
32. Fodor JG, Frohlich JJ, Genest JJ Jr, McPherson PR. Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. Can Med Assoc J 2000; 162: 1441-1447.
33. Assman G, Cullen P, Schulte H. The Munster heart study (PROCAM): Results of follow-up at 8 years. Eur Heart J 1998; 19 (Suppl. A): A2-A11.
34. Meltzer S, Leiter L, Daneman D et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Canadian Diabetes Association. Can Med Assoc J 1998; 159 (Suppl. 8): S1-S29.
35. Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. Can Med Assoc J 2003; 169: 921-924.
36. ATPIII. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on 'Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)'. NIH Publication no. 01-3670. Bethesda, MD, National Cholesterol Education Program, National Heart, Lung and Blood Institute, National Institutes of Health, 2001.
37. Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS. Incidence of morphological and lipid abnormalities: Gender and treatment differentials after initiation of first antiretroviral therapy. Int J Epidemiol 2002; 31: 1016-1020.
38. HSF. The Growing Burden of Heart Disease and Stroke in Canada, 2003. Ottawa, Canada: The Heart and Stroke Foundation of Canada, 2003.
39. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis 2004; 23: 625-630.
40. Hadigan C, Meigs JB, Wilson PW et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003; 36: 909-916.
41. Fauvel J, Bonnet E, Ruidavets JB et al. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001; 15: 2397-2406.
42. Bollens D, Guiguet M, Tangre P et al. Major hypertriglyceridemia in HIV-infected patients on antiretroviral therapy: A role of the personal and family history. Infection 2004; 32: 217-221.
43. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-1883.
44. Nolan D, Mallal S. Antiretroviral-therapy-associated lipoatrophy: current status and future directions. Sex Health 2005; 2: 153-163.
45. Chu JW, Abbasi F, Beatty GW et al. Methods for quantifying insulin resistance in human immunodeficiency virus-positive patients. Metabolism 2003; 52: 858-861.
46. Gelato MC, Mynarcik DC, Quick JL et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: A pilot study. J Acquir Immune Defic Syndr 2002; 31: 163-170.
47. Carr A, Workman C, Carey D et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. Lancet 2004; 363: 429-438.
48. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J 1994; 308: 367-372.
49. Badiou S, Merle De Boever C, Dupuy AM, Baillat V, Cristol JP, Reynes J. Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults. Atherosclerosis 2004; 172: 273-279.
50. Truchis P, Kirstetter M, Perier A et al. Treatment of hypertriglyceridemia in HIV-infected patients under HAART by (n-3) polyunsaturated fatty acids: A double-blind randomized controlled trial in 122 patients. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2005.
51. Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial. J Am Med Assoc 2002; 288:
52. Carr A, Hudson J, Chuah J et al. HIV protease inhibitor substitution in patients with lipodystrophy: A randomized, controlled, open-label, multicentre study. AIDS 2001; 15: 1811-1822.
53. Petit JM, Duong M, Masson D et al. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. Eur J Clin Invest 2004; 34: 569-575.
54. Wensing AM, Reedijk M, Richter C, Boucher CA, Borleffs JC. Replacing ritonavir by nelfinavir or nelfinavir/saquinavir as part of highly active antiretroviral therapy leads to an improvement of triglyceride levels. AIDS 2001; 15: 2191-2193.
55. Ruiz L, Negredo E, Domingo P et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001; 27: 229-236.
56. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-1019.
57. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naïve subjects. J Acquir Immune Defic Syndr 2003; 32: 18-29.